Stock Events

Stock Events

MindBio Therapeutics 

$0.149000
0
-$0.02-11.26% Thursday 18:23

Statistics

Day High
0.2013
Day Low
0.2013
52W High
0.2013
52W Low
0.149
Volume
100
Avg. Volume
3,120
Mkt Cap
1.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2022
2023
2024
0Revenue
-1.8MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBQIF. It's not an investment recommendation.
Palantir Technologies
2
PLTR.NEO
Manulife Financial
2
MFC.TO
Saputo
2
SAP.TO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.84B
Compass Pathways focuses on psilocybin therapy for depression, directly competing in the psychedelic-assisted therapy space.
AtaiBeckley
ATAI
Mkt Cap2.74B
ATAI Life Sciences works on mental health treatments using psychedelics and other compounds, overlapping with MindBio's therapeutic areas.
GH Research
GHRS
Mkt Cap1.94B
GH Research focuses on developing 5-MeO-DMT therapies for depression, a direct competitor in psychedelic research for mental health.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics explores psilocybin for the treatment of various ailments, including mental health disorders, competing with MindBio.
Red Light Holland
TRIP.CN
Mkt Cap17.87M
Red Light Holland produces and sells truffles to the legal, recreational market but is moving towards therapeutic uses, indirectly competing.
Mydecine Innovations Group
MYCO.CN
Mkt Cap407,570
Mydecine Innovations Group focuses on developing and commercializing psychedelic medicines, directly competing in MindBio's market.

About

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Justin Adam Hanka
Country
Canada
ISIN
CA60256C2076
WKN
000A41RJS

Listings

STU
DE
WF60.STU
MU
DE
WF6.MU
F
DE
WF60.F
MU
DE
WF60.MU

0 Comments

Share your thoughts

FAQ

What is MindBio Therapeutics stock price today?▼
The current price of MBQIF is $0.15 USD — it has decreased by -11.26% in the past 24 hours. Watch MindBio Therapeutics stock price performance more closely on the chart.
What is MindBio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange MindBio Therapeutics stocks are traded under the ticker MBQIF.
What is MindBio Therapeutics market cap?▼
Today MindBio Therapeutics has the market capitalization of 1.09M
What is MindBio Therapeutics revenue for the last year?▼
MindBio Therapeutics revenue for the last year amounts to 0 USD.
What is MindBio Therapeutics net income for the last year?▼
MBQIF net income for the last year is -1.8M USD.
In which sector is MindBio Therapeutics located?▼
MindBio Therapeutics operates in the Other sector.
When did MindBio Therapeutics complete a stock split?▼
MindBio Therapeutics has not had any recent stock splits.
Where is MindBio Therapeutics headquartered?▼
MindBio Therapeutics is headquartered in Vancouver, Canada.